Laila al-Shaar

Global Medical Director in Medical Evidence Generation at Sanofi, Rare Diseases Launch and Pipeline

Role
Global Medical Director in Medical Evidence Generation, Rare Diseases Launch and Pipeline at Sanofi
Location
Cambridge, MA, US
LinkedIn followers
500 followers

About Laila al-Shaar

Global Medical Director leading integrated evidence-generation strategies across rare-disease pipeline and launch assets. Drives alignment and strategic partnerships across Medical Affairs, R&D, HEOR, Regulatory, Market Access, and Commercial teams to deliver decision-enabling evidence for regulators, payers, and clinicians. Applies deep expertise in epidemiology and real-world evidence, supported by 15+ year-experience and 65+ peer-reviewed publications, to translate complex data into launch-ready, impact-driven strategies that advance programs and improve outcomes for patients with rare diseases.

Experience

  1. Global Medical Director in Medical Evidence Generation, Rare Diseases Launch and Pipeline

    Sanofi

    Jan 2025 — Present · Cambridge, MA, US

Education

  • American University of Beirut

    MS, Biochemistry

    2004 — 2006

  • Harvard University

    PhD, Population Health Sciences

    2016 — 2019

  • American University of Beirut

    MPH, Public Health-Biostatistics and Epidemiology

    2008 — 2010

Skills

  • Teaching
  • Epidemiology
  • Biostatistics
  • Molecular Biology
  • Program Evaluation
  • Public Health
  • Medical Education
  • Laboratory
  • Statistics
  • Data Analysis
  • Healthcare
  • Research
  • Clinical Research
  • Spss
  • Literature Reviews

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Laila al-Shaar — Global Medical Director in Medical Evidence Generation, Rare Diseases Launch and Pipeline at Sanofi in Cambridge, MA, US | Unifers